Sanofi announced the acquisition of Principia Biopharma in a deal valued at about $3.68 billion as the French company continues to transform its R&D division to more heavily emphasize oncology and other lucrative programs.
South San Francisco-based Principia Biopharma is looking to become a publicly traded company and is aiming for a $86 million initial public offering.
